Cargando…
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
INTRODUCTION: A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility to poly(ADP-ribose) polymerase (PARP) inhibitor...
Autores principales: | Carlson, Alexander S., Acevedo, Rigo I., Lim, Daniel M., Gulati, Roman, Gawne, Agnes, Sokolova, Alexandra O., Cheng, Heather H., Nelson, Peter S., Montgomery, R. Bruce, Yu, Evan Y., Schweizer, Michael T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526881/ https://www.ncbi.nlm.nih.gov/pubmed/32997692 http://dx.doi.org/10.1371/journal.pone.0239686 |
Ejemplares similares
-
Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021) -
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018) -
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018) -
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
por: Cheng, Heather H., et al.
Publicado: (2023) -
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)